SCHEMBL7761933

SCHEMBL7761933

CN(C)C(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.58
CTSD P07339 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
HPGD P15428 2/20 0.53
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SLC6A4 P31645 1/20 0.51
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
LMNA P02545 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706905 0.84 GPR35 (0.58) ALDH1A1SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL5913897 0.84 TSHR (0.68) ALDH1A1SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL9135346 0.83 ATM (0.57) ALDH1A1CTSDSMN1; SMN2KMT2AKDM4E
SCHEMBL11687293 0.83 ALDH1A1 (0.51) ALDH1A1CTSDSMN1; SMN2HPGDKDM4E
Hydrochloric Acid SCHEMBL11687297 0.83 ALDH1A1 (0.51) ALDH1A1CTSDSMN1; SMN2HPGDKMT2A
SCHEMBL1255756 0.83 SLC6A4 (0.50) ALDH1A1CTSDSMN1; SMN2HPGDKMT2A
SCHEMBL18894126 0.83 TSHR (0.49) ALDH1A1CTSDSMN1; SMN2HPGDKMT2A
SCHEMBL29550783 0.82 L3MBTL1 (0.56) ALDH1A1SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL7737869 0.82 ALDH1A1 (0.50) ALDH1A1CTSDSMN1; SMN2HPGDKDM4E
Trimethylammonium SCHEMBL28659606 0.81 TSHR (0.64) ALDH1A1CTSDKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108290860-B Iminotetrahydropyrimidinone derivatives as PLASMEPSIN V inhibitors UCB生物制药有限责任公司 2021-08-10 CN disclosed
CN-107382643-B FeCl3Catalytic synthesis method of amide compounds 中国人民解放军63975部队 2020-11-20 CN disclosed
CN-106187803-A The synthetic method of the amides compound that a kind of phosphorus oxychloride promotes 中国人民解放军63975部队 2016-12-07 CN disclosed
CN-1826333-B Diamine derivatives DAIICHI SANKYO CO LTD 2012-12-26 CN disclosed
CN-102173999-A Method for synthesizing 2-amino-N,N-dimethylbenzamide YANCHENG INST TECHNOLOGY 2011-09-07 CN disclosed
CN-101056628-B Ester derivatives and medicinal use thereof JAPAN TOBACCO INC 2011-05-25 CN disclosed
CN-101031565-B Substituted 2H-1, 3-benzoxazin-4 (3H) -ones PORTOLA PHARM INC 2010-09-29 CN disclosed
CN-101838218-A Ester compound and pharmaceutical use of the same JAPAN TOBACCO INC 2010-09-22 CN disclosed
CN-1630629-B Ester compound and medical use thereof JAPAN TOBACCO INC 2010-05-05 CN disclosed
CN-100545160-C Diamine derivative DAIICHI SEIYAKU CO (JP) 2009-09-30 CN disclosed
CN-1751025-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-03-22 CN disclosed
CN-1630629-A Ester compound and medical use thereof JAPAN TOBACCO INC (JP) 2005-06-22 CN disclosed
CN-1312817-A Dolastatin 15 derivatives BASF AG (DE) 2001-09-12 CN disclosed
US-20010018422-A1 Dolastatin 15 derivatives BASF AKTIENGESELLSCHAFT 2001-08-30 US disclosed
EP-1093460-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2001-04-25 EP disclosed
WO-2000002906-A1 DOLASTATIN 15 DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-01-20 WO disclosed
US-5985837-A CELL GROWTH INHIBITOR PEPTIDES; TREATING CANCER IN A MAMMAL BASF AKTIENGESELLSCHAFT (DE) 1999-11-16 US disclosed
US-5688795-A URINARY TRACTS OBSTRUCTION SYNTEX (U.S.A.) INC. (US) 1997-11-18 US disclosed
CN-1136039-A [3- (4-phenylpiperazin-1-yl) propylamino, thio and oxy ] -pyridine, pyrimidine and benzene derivatives HOFFMANN LA ROCHE (CH) 1996-11-20 CN disclosed
EP-0711757-A1 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists F. Hoffmann-La Roche AG (CH) 1996-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018422-A1 Dolastatin 15 derivatives SLCO2B1, SLCO2A1, DDOST ALDH1A1 768/4885CTSD 1623/4885SMN1; SMN2 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.